News

Liam Payne: Late One Direction Singer’s Autopsy Reveals Several Drugs In His System

BY Dora Abena Dzaka October 22, 2024 11:46 AM EDT
Photo Credit Instagram @liampayne

One Direction singer, Liam Payne, died on October 16 after falling from a third-floor hotel balcony in Buenos Aires. His body is said to remain in Argentina until a complete autopsy is conducted.

An initial preliminary autopsy report from the Argentinian Public Prosecutor’s Office found that Payne died of “multiple traumas” and “internal and external bleeding.” 

The report stated that Payne’s head injuries were sufficient to cause death, and the cause of death was related to the height of his fall.

An overall of 25 injuries were reported on Payne’s body but according to ABC News, a source said on October 21 that Liam Payne had “multiple substances” in his system when he died.

Again, one of the substances reportedly included “pink cocaine, a recreational drug that is typically a mix of several drugs, including methamphetamine, ketamine, MDMA, and others, as well as cocaine, benzodiazepine, and crack. 

An improvised aluminum pipe to ingest drugs was also found in his hotel room, according to the sources.

However, it said police tests on a white powder found in his hotel room had so far proved “inconclusive.”

 The New York Times, also noted that the final autopsy results are pending, with no confirmed date for their release.

A spokesman for the Buenos Aires police also said the preliminary toxicological report was handed over to the local prosecutor’s office, which is investigating the death as a matter of protocol.

Liam’s dad, Geoff, is in Argentina to speed up the repatriation of his body but is understood to have been told he will not be able to fly the mortal remains back to the UK until the 31-year-old’s death is confirmed “scientifically.” 

Face2face Africa | Afrobeatz+ | BlackStars

Keep Up With Global Black News and Events

Sign up to our newsletter to get the latest updates and events from the leading Afro-Diaspora publisher straight to your inbox, plus our curated weekly brief with top stories across our platforms.

No, Thank You